Penn Heart and Vascular

Clinical Trials at the Interventional Cardiology Program

Clinical Trials

Interventional Cardiology

The PARTNER Transcatheter AVR Trial

Penn Medicine was one of the first sites to participate in and was a leading enrollment site for the Placement of Aortic Transcatheter Valves (PARTNER) trial comparing the safety and effectiveness of the Edwards SAPIEN® transcatheter heart valve to that of standard valve replacement surgery (cohort A) or "non-operative" patients (cohort B) in high-risk, symptomatic patients with severe aortic stenosis. In the PARTNER trial, cohort B showed the rate of death from cardiovascular causes at one year (Kaplan–Meier analysis) was also lower in the transcatheter aortic-valve implantation (TAVI*) group than in the standard therapy group.
* TAVI procedure is now referred to as TAVR (transcatheter aortic valve replacement).

Learn more about the PARTNER Transcatheter AVR Trial

The PARTNER Trial: Phase II

PARTNER II, will evaluate the SAPIEN XT transcatheter aortic valve in high-risk, symptomatic patients with severe aortic stenosis. The Sapien XT valve has a lower profile than its predecessor that can be delivered through an 18F sheath, permitting stent placement for the broad population of patients with smaller femoral arteries who were previously excluded from stent therapy.

Learn more about the PARTNER Trial: Phase II

Everest II

The EVEREST II trial examined the use of the MitraClip for the percutaneous repair of mitral valve regurgitation in patients with moderately severe or severe mitral regurgitation. The Hospital of the University of Pennsylvania was among the first in the nation to perform percutaneous repair for mitral valve regurgitation in 2005 and is one of only 37 hospitals nationwide (and the only one in the region) using the MitraClip device. The trial's PI is Howard C. Herrmann, MD.

Learn more about Everest II

Placement of Aortic Transcatheter valves (PARTNER) trial

This trial examines the use of transcatheter aortic-valve implantation (TAVI) in high-risk patients with severe aortic stenosis considered unsuitable candidates for surgery.

AMPLATZER® Cardiac Plug (ACP) Clinical Trial

The ACP trial is designed to evaluate the safety and effectiveness of the AMPLATZER® Cardiac Plug for left atrial appendage closure (investigational device) in people with non-valvular atrial fibrillation compared to the use of warfarin.

Upcoming Events